Pluristem Therapeutics: Gets FDA nod to begin late-stage study of muscle treatment

Pluri

25/04/2018 12:36

** Drug developer's shares  PSTI.O  up 4.2 pct at $1.25
premarket on FDA nod to start phase 3 study of muscle treatment
    ** Stock among top pct gainers across U.S. exchanges before
the bell
    ** Company receives FDA clearance for its late-stage study
of PLX-PAD cell therapy to treat muscle injury following hip
fracture surgery  urn:newsml:reuters.com:*:nGNXspqnQ
    ** Company to begin patient enrollment in U.S. and Europe
this year
    ** As of Tuesday's close, shares down 13 pct YTD

 (Reporting by Amy Caren Daniel in Bengaluru)
 ((Reuters Messaging:
Amy.CarenDaniel.thomsonreuters.com@reuters.net))